Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article

Robert H. J. Hargreaves¹, John A. Hartley², John Butler^1,3,*

Show Less

¹ CRC Drug Development Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester, M20 4BX, U.K.

² CRC Drug-DNA Interactions Research Group, Department of Oncology, Royal Free and University College Medical School, UCL, 91 Riding House Street, London W1P 8BT, U.K.

³ Department of Biological Sciences, Salford University, Salford M5 4WT, United Kingdom

Front. Biosci. (Landmark Ed) 2000, 5(4), 172–180; https://doi.org/10.2741/hargreav

Published: 1 November 2000

Download PDF

Cite

Abstract

Aziridinyl quinones can be activated by cellular reductases eg. DT-diaphorase and cytochrome P450 reductase to form highly reactive DNA alkylating agents. The mechanisms by which this activation and alkylation take place are many and varied. Using clinically relevant and experimental agents this review will describe many of these mechanisms. The agents discussed are Mitomycin C, EO9 and analogues, diaziridinylbenzoquinones and the pyrrolo[1, 2-alpha]benzimidazolequinones.

Keywords

DNA alkylation

Quinone Anti-Cancer Agents

Review

Previous article in this issue

Next article in this issue

Front. Biosci. (Landmark Ed) Print ISSN 2768-6701 Electronic ISSN 2768-6698